1. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer- SIOP-European Neuroblastoma study 
Angela Di Giannatale, Nathalie Dias-Gastellier, Annick Devos, Kieran Mc Hugh, Ariane Boubaker, Frederic Courbon, Arnaud Verschuur, Stéphane Ducassoul, Katty Malekzadeh, Michela Casanova, Loredana Amoroso, Pascal Chastagner, Christian M. Zwaan, Caroline Munzer, Isabelle Aerts, Judith Landman-Parker, Riccardo Riccardi, Marie-Cecile Le Deley, Birgit Geoerger, Hervé Rubie 
European Journal of Cancer 
Volume 50, Issue 1, Pages (January 2014)
DOI: /j.ejca
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Fig. 1
Patient’s response at Cycle 2 and best response in all 38 treated and for response evaluable patients. ∗Stop Treatment after one cycle for toxicity; ∗∗Clinical PD after one cycle; CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progression disease.
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Fig. 2
Progression-free survival (A) and Overall survival (B) in all 38 patients included and treated with topotecan–temozolomide (TOTEM) combination as compared to 25 patients treated with temozolomide alone. Graphs are estimated using Kaplan–Meier method and represent data from the here presented 38 patients treated with TOTEM combination (red) and 25 patients treated with Temozolomide alone (blue) reported by Rubie et al. [10]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
European Journal of Cancer  , DOI: ( /j.ejca )
Copyright © 2013 Elsevier Ltd Terms and Conditions